Adam J. Olszewski, MD, associate professor of medicine at Brown University and lymphoma clinician at Rhode Island Hospital in Providence, Rhode Island, discusses promising results from a Phase 1b/2 study (NCT03677154) of mosunetuzumab (Lunsumio) in patients with Elderly/unwell patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
According to the results of the study, treatment with moxonetuzumab was effective and induced durable complete responses (CR) in this patient population. A total of 43% of patients achieved CR, with a median duration of response of 15.8 months.
Furthermore, 38% of patients were alive after 1 year without any evidence of disease. Overall, these results suggest that moxonetuzumab may be an effective treatment option for older/unfit patients with DLBCL who are not candidates for standard chemotherapy.
0:10 | These responses are long-lasting. Currently, the median duration of complete remission is up to 3 years, and we will see if these patients relapse. So far, only 3 of 23 patients with complete remission have relapsed. The other 20 people are continuing to complete their responses.
0:28 | 0:28 Among the 54 patients in my clinic and other clinics of the researchers involved in this trial, 20 were elderly patients without any evidence of lymphoma. Some (patients) died of natural causes because it was an older population. We face challenges related to the coronavirus pandemic. Mosunetuzumab is a B-cell depleting therapy that may increase the risk of serious COVID-19 complications, but we have learned how to manage it, especially using preventive measures and available treatments. So overall, one year after starting this treatment, three-quarters of these patients were alive, and about 38 percent were alive without any evidence of disease.